Cargando…

Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity

BACKGROUND: Fatigue is common in Crohn's disease (CD) and ulcerative colitis (UC). Data on fatigue in newly diagnosed patients are unavailable. AIM: To report prevalence of fatigue in newly diagnosed CD and UC patients and examine its association with health-related quality of life (HRQOL), dep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, B L, Zoëga, H, Shah, S A, LeLeiko, N, Lidofsky, S, Bright, R, Flowers, N, Law, M, Moniz, H, Merrick, M, Sands, B E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Depression and Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670472/ https://www.ncbi.nlm.nih.gov/pubmed/24612278 http://dx.doi.org/10.1111/apt.12659

Ejemplares similares

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial
por: Jongsma, Maria M E, et al.
Publicado: (2022)

Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease
por: Wils, Pauline, et al.
Publicado: (2023)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Environmental risk factors for inflammatory bowel disease
por: Singh, Noreen, et al.
Publicado: (2022)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study
por: Ma, Christopher, et al.
Publicado: (2017)

Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis
por: Dubinsky, Marla C, et al.
Publicado: (2023)

Elevated ectodomain of type 23 collagen is a novel biomarker of the intestinal epithelium to monitor disease activity in ulcerative colitis and Crohn's disease
por: Manon‐Jensen, T., et al.
Publicado: (2021)

Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose‐effect relationship
por: Wijnands, Anouk M., et al.
Publicado: (2023)

Identifying and understanding disease burden in patients with inflammatory bowel disease
por: Christensen, Katrine Risager, et al.
Publicado: (2022)

Creeping fat formation and interaction with intestinal disease in Crohn's disease
por: Yin, Yi, et al.
Publicado: (2022)

Higher Activity of the Inducible Nitric Oxide Synthase Contributes to Very Early Onset Inflammatory Bowel Disease
por: Dhillon, Sandeep S, et al.
Publicado: (2014)

Diversion proctocolitis and the problem of the forgotten rectum in inflammatory bowel diseases: A systematic review
por: Dal Buono, Arianna, et al.
Publicado: (2021)

Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
por: Cozijnsen, M A, et al.
Publicado: (2016)

Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease
por: Schwerd, Tobias, et al.
Publicado: (2017)

Faecal metabolome and its determinants in inflammatory bowel disease
por: Vich Vila, Arnau, et al.
Publicado: (2023)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Increased Epithelial Gaps in the Small Intestine Are Predictive of Hospitalization and Surgery in Patients With Inflammatory Bowel Disease
por: Turcotte, Jean-Francois, et al.
Publicado: (2012)

Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study
por: Clooney, Adam G, et al.
Publicado: (2021)

Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance
por: Aschenbrenner, Dominik, et al.
Publicado: (2021)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Increased risk of genital warts in inflammatory bowel disease: A Danish registry‐based cohort study (1996–2018)
por: Elmahdi, Rahma, et al.
Publicado: (2022)

A microbial signature for Crohn's disease
por: Pascal, Victoria, et al.
Publicado: (2017)

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis
por: Kennedy, N. A., et al.
Publicado: (2016)

Validation of stricture length, duration and obstructive symptoms as predictors for intervention in ileal stricturing Crohn's disease
por: El Ouali, Sara, et al.
Publicado: (2022)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers
por: Roberts, Carol L, et al.
Publicado: (2010)

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Bacterial protein signals are associated with Crohn’s disease
por: Juste, Catherine, et al.
Publicado: (2014)

Treat‐to‐target and sequencing therapies in Crohn's disease
por: Garcia, Nicole M., et al.
Publicado: (2022)

Changing paradigms in management of inflammatory bowel disease
por: Mao, Ren, et al.
Publicado: (2022)

New endoscopic tools in inflammatory bowel disease
por: Nardone, Olga Maria, et al.
Publicado: (2022)

Effectiveness of disease-specific cognitive–behavioural therapy on depression, anxiety, quality of life and the clinical course of disease in adolescents with inflammatory bowel disease: study protocol of a multicentre randomised controlled trial (HAPPY-IBD)
por: van den Brink, Gertrude, et al.
Publicado: (2016)

Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
por: Thunberg, Joel, et al.
Publicado: (2022)

Cytomegalovirus colitis in inflammatory bowel disease and after haematopoietic stem cell transplantation: diagnostic accuracy, predictors, risk factors and disease outcome
por: Mavropoulou, Eirini, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_snv2kuiv66ikr1602mtqodf56g